Table 1.
Demographics and clinical characteristics of patients in the primary and validation cohorts
| Characteristic | All Patients (N = 224) |
Primary Cohort (N = 93) |
Validation Cohort 1 (N = 68) |
Validation Cohort 2 (N = 63) |
|---|---|---|---|---|
| Sex | ||||
| Male | 184 (82.1%) | 80 (86.0%) | 52 (76.5%) | 52 (82.5%) |
| Female | 40 (17.9%) | 13 (14.0%) | 16 (23.5%) | 11 (17.5%) |
| Smoking | ||||
| Current or Former | 107 (47.8%) | 42 (45.2%) | 46 (67.6%) | 19 (30.2%) |
| Never | 117 (52.2%) | 51 (54.8%) | 22 (32.4%) | 44 (69.8%) |
| Age | ||||
| Mean (range) | 65 (27–86) | 67 (31–85) | 61 (27–76) | 66 (29–86) |
| Pathology | ||||
| Adenocarcinoma | 149 (66.5%) | 57 (61.3%) | 54 (79.4%) | 38 (60.3%) |
| Squamous Cell Carcinoma | 75 (33.5%) | 36 (38.7%) | 14 (20.6%) | 25 (39.7%) |
| Clinical Stage | ||||
| III | 36 (16.1%) | 13 (14.0%) | 4 (5.9%) | 19 (30.2%) |
| IV | 188 (83.9%) | 80 (86.0%) | 64 (94.1%) | 44 (69.8%) |
| Response | ||||
| CR | - | - | - | - |
| PR | 73 (32.6%) | 34 (36.5%) | 15 (22.1%) | 24 (38.1%) |
| SD | 78 (34.8%) | 42 (45.2%) | 13 (19.1%) | 23 (36.5%) |
| PD | 73 (32.6%) | 17 (18.3%) | 40 (58.8%) | 16 (25.4%) |